Literature DB >> 6777437

Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans.

A S Cross, J C Sadoff, B H Iglewski, P A Sokol.   

Abstract

Levels of antibody to toxin A of Pseudomonas aeruginosa were determined by a solid-phase radioimmunoassay. Mean (+/- SEM) peak levels of IgG in 24 normal soldiers were 2.6 +/- 0.5 microgram/ml, white mean peak levels in 12 patients colonized with and 13 patients infected in sites other than the blood with toxin A-producing strains were 16.7 +/- 7.0 and 17.1 +/- 4.4 microgram/ml, respectively. Levels of IgG were determined in 52 patients with pseudomonas bacteremia, and those surviving and those dying of bacteremia due to toxin A-producing strains had mean peak levels of 25.8 +/- 5.5 and 4.6 +/- 2.0 microgram/ml, respectively. The antitoxin response in sequential bacteremic sera began shortly after onset of bacteremia and decreased gradually, but antitoxin could be recalled promptly upon reinfection with Pseudomonas. Death from pseudomonas bacteremia was significantly associated with infection by a toxin A-producing strain, presence of underlying disease, hypotension, and antitoxin level of < 2 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6777437     DOI: 10.1093/infdis/142.4.538

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

1.  [Use of pseudomonas immunoglobulin in ventilated patients at an interdisciplinary surgical intensive care station].

Authors:  I Class; W Junginger; T Klöss
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 2.  Mechanisms in acute septic cardiomyopathy: evidence from isolated myocytes.

Authors:  K Werdan; U Müller; C Reithmann; A Pfeifer; S Hallström; B Koidl; G Schlag
Journal:  Basic Res Cardiol       Date:  1991 Sep-Oct       Impact factor: 17.165

3.  Virulence determinants in Pseudomonas aeruginosa strains from urinary tract infections.

Authors:  P Visca; F Chiarini; A Mansi; C Vetriani; L Serino; N Orsi
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

4.  Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.

Authors:  G B Pier; S E Bennett
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

5.  Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Furer; J C Sadoff; R Germanier
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

Review 6.  New insights into the epidemiology, pathogenesis and therapy of Pseudomonas aeruginosa infections.

Authors:  S J Cryz
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

7.  Biological effects of Pseudomonas aeruginosa exotoxin A: lymphoproliferation of T lymphocytes in athymic mice.

Authors:  P S Holt; M L Misfeldt
Journal:  Eur J Epidemiol       Date:  1988-03       Impact factor: 8.082

8.  Proteinases produced by pseudomonads isolated from sheep fleece.

Authors:  C J London; I P Griffith; A A Kortt
Journal:  Appl Environ Microbiol       Date:  1984-01       Impact factor: 4.792

9.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.